Hema Dave
Impact in
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- CAR-T cell therapy research
- Polyomavirus and related diseases
Papers in
- Oncology 20
- CAR-T cell therapy research 12
- Polyomavirus and related diseases 5
- Viral-associated cancers and disorders 3
-
- Lymphoma Diagnosis and Treatment 13
- Co-authors
- Catherine M. Bollard (15 shared papers)Miriam R. Anver (2 shared papers)Elizabeth J. Shpall (4 shared papers)Donna O. Butcher (2 shared papers)Patrick J. Hanley (5 shared papers)Terzah M. Horton (3 shared papers)Kathleen M. McCarten (2 shared papers)Frank Keller (3 shared papers)
- Journals
- Blood Advances (6 papers)Molecular Therapy — Methods & Clinical Development (2 papers)Blood (2 papers)Cytotherapy (2 papers)PLoS ONE (1 paper)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Hema Dave
31 papers receiving 544 citations
Peers
Comparison fields: 5 of 50
- Pathology and Forensic Medicine 205
- Oncology 277
- Neurology 105
- Genetics 47
- Hematology 50
Countries citing papers authored by Hema Dave
This map shows the geographic impact of Hema Dave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hema Dave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hema Dave more than expected).
Fields of papers citing papers by Hema Dave
This network shows the impact of papers produced by Hema Dave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hema Dave. The network helps show where Hema Dave may publish in the future.
Co-authors
The 25 scholars most cited alongside Hema Dave, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 110 | |
| 2 | 2017 | 107 | |
| 3 | 2012 | 43 | |
| 4 | 2019 | 40 | |
| 5 | 2017 | 39 | |
| 6 | 2019 | 21 | |
| 7 | 2022 | 19 | |
| 8 | 2019 | 18 | |
| 9 | 2021 | 18 | |
| 10 | 2017 | 16 | |
| 11 | 2021 | 15 | |
| 12 | 2021 | 14 | |
| 13 | 2023 | 10 | |
| 14 | 2021 | 10 | |
| 15 | 2019 | 10 | |
| 16 | 2019 | 10 | |
| 17 | 2013 | 8 | |
| 18 | 2014 | 8 | |
| 19 | 1988 | 7 | |
| 20 | 2021 | 6 |
About Hema Dave
Hema Dave is a scholar working on Oncology, Pathology and Forensic Medicine, Neurology, Immunology and Hematology, having authored 32 papers that have together received 554 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (12 papers), Acute Lymphoblastic Leukemia research (5 papers), Polyomavirus and related diseases (5 papers), CNS Lymphoma Diagnosis and Treatment (5 papers), Virus-based gene therapy research (4 papers), Immune Cell Function and Interaction (4 papers) and Viral-associated cancers and disorders (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (205 citations), Oncology (277 citations), Neurology (105 citations), Genetics (47 citations) and Hematology (50 citations). Hema Dave has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Catherine M. Bollard, Miriam R. Anver, Elizabeth J. Shpall, Donna O. Butcher, Patrick J. Hanley, Terzah M. Horton, Kathleen M. McCarten, Frank Keller, David C. Hodgson and Qinglin Pei. Their work appears in journals such as Blood Advances, Molecular Therapy — Methods & Clinical Development, Blood, Cytotherapy and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.